Skip to main content
. 2019 Jun 13;11(1):142–150. doi: 10.1111/jdi.13075

Figure 2.

Figure 2

Change in glycated hemoglobin (HbA1c) from baseline to week 26 in Chinese patients with type 2 diabetes who were treated with dulaglutide 1.5 mg, dulaglutide 0.75 mg or glimepiride. †Difference in least‐squares mean (LSM; 95% confidence interval) between dulaglutide 1.5 mg and glimepiride. Dulaglutide 1.5 mg was non‐inferior and superior to glimepiride (both P < 0.001). ‡Difference in LSM (95% confidence interval) between dulaglutide 0.75 mg and glimepiride. Dulaglutide 0.75 mg was non‐inferior (P < 0.001) and superior (P = 0.002) to glimepiride.